ProPhase Labs (PRPH) announced that its clinical study by Hartley et al. validating the BE-Smart esophageal cancer test has been accepted for publication in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association. This milestone marks a turning point as ProPhase moves from validation to commercialization of the BE-Smart assay. With approximately 7 million upper endoscopies performed annually in the U.S. for GERD and Barrett’s Esophagus surveillance, BE-Smart is positioned to address a total addressable market of roughly $7-$14 billion. The company is now advancing regulatory preparations and scaling laboratory efforts to support clinical testing in partnership with leading gastroenterology practices. In parallel, ProPhase is pursuing collaborations with key opinion leaders and health-system partners to integrate BE-Smart into patient-care workflows and clinical decision-making. These efforts will enable physicians to order the test through standard pathology channels, with a phased rollout planned to begin in 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRPH:
- ProPhase Labs files to sell 226.31M shares of common stock for holders
- ProPhase Labs Signs Sales Agreement with WestPark Capital
- ProPhase announces three COVID-19 testing companies filed for reorganization
- ProPhase Labs continues exploration of crypto treasury strategy
- ProPhase Labs Partners with ThinkEquity for $6M Placement